Photo from wikipedia
New immunotherapeutic approaches are urgently needed for metastatic rhabdomyosarcoma, which is associated with poor survival and unsatisfactory treatment outcomes. Platelet‐derived growth factor receptor α (PDGFRA) plays an essential role in… Click to show full abstract
New immunotherapeutic approaches are urgently needed for metastatic rhabdomyosarcoma, which is associated with poor survival and unsatisfactory treatment outcomes. Platelet‐derived growth factor receptor α (PDGFRA) plays an essential role in the onset and development of rhabdomyosarcoma and is a new potential therapeutic target for rhabdomyosarcoma. The objective of this study was to generate humanized PDGFRA single‐chain variable fragment‐based chimeric antigen receptor (CAR)‐modified T cells (CAR‐T cells) against PDGFRA‐positive rhabdomyosarcoma.
Journal Title: Cancer
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!